1. Home
  2. REBN vs ENSC Comparison

REBN vs ENSC Comparison

Compare REBN & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reborn Coffee Inc.

REBN

Reborn Coffee Inc.

HOLD

Current Price

$1.47

Market Cap

8.7M

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.11

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REBN
ENSC
Founded
2015
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7M
6.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
REBN
ENSC
Price
$1.47
$1.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
58.5K
419.4K
Earning Date
11-19-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,663,303.00
$4,487,973.00
Revenue This Year
$335.98
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.09
1.51
52 Week Low
$1.20
$1.08
52 Week High
$8.30
$10.96

Technical Indicators

Market Signals
Indicator
REBN
ENSC
Relative Strength Index (RSI) 39.64 28.85
Support Level $1.36 $1.08
Resistance Level $1.56 $1.24
Average True Range (ATR) 0.13 0.13
MACD -0.01 -0.01
Stochastic Oscillator 19.17 9.26

Price Performance

Historical Comparison
REBN
ENSC

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: